about
Xenon pretreatment may prevent early memory decline after isoflurane anesthesia and surgery in miceHeat shock protein 72 overexpression prevents early postoperative memory decline after orthopedic surgery under general anesthesia in miceLate HIV diagnosis is a major risk factor for intensive care unit admission in HIV-positive patients: a single centre observational cohort studyProtective effects of hydrogen enriched saline on liver ischemia reperfusion injury by reducing oxidative stress and HMGB1 release.Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration.Central nervous system inflammation in disease related conditions: mechanistic prospects.Neuroinflammation: the role and consequences.Xenon Treatment Protects against Remote Lung Injury after Kidney Transplantation in Rats.Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells.Revised Baux Score and updated Charlson comorbidity index are independently associated with mortality in burns intensive care patients.The responsiveness of the Chelsea Critical Care Physical Assessment tool in measuring functional recovery in the burns critical care population: an observational study.Geographical analysis of socioeconomic factors in risk of domestic burn injury in London 2007-2013.The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction.Incidence of bacteraemia in a neurocritical care unit.ITU outcome of postcardiac arrest patients.Cognitive decline following major surgery is associated with gliosis, β-amyloid accumulation, and τ phosphorylation in old mice.Fluid creep in burn resuscitation: the tide has not yet turned.Influence of anaesthetic factors on skin graft viability in a burns ICU.Pre-treatment with isoflurane ameliorates renal ischemic-reperfusion injury in mice.Serotonin syndrome triggered by tramadol.Low socioeconomic status, ethnicity and geographical location confers high risk of significant accidental burns injuries in London.Initial tracheal tube size for patients with burns.Validation of the laboratory risk indicator for necrotising fasciitis scoring system (LRINEC) in a Northern European population.Severity of acute ocular involvement is independently associated with time to resolution of ocular disease in toxic epidermal necrolysis patients.The therapeutic potential of atorvastatin in a mouse model of postoperative cognitive decline.The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats.Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease.Comment on Xirouchaki et al.: Impact of lung ultrasound on clinical decision making in critically ill patients.Continuation of statin therapy in patients with presumed infectionThe psychological and neurocognitive consequences of critical illness. A pragmatic review of current evidenceImplications for COVID-19 triage from the ICNARC report of 2204 COVID-19 cases managed in UK adult intensive care unitsCOVID-19 genomic susceptibility: Definition of ACE2 variants relevant to human infection with SARS-CoV-2 in the context of ACMG/AMP GuidanceEarly detection of severe COVID-19 disease patterns define near real-time personalised care, bioseverity in males, and decelerating mortality rates.
P50
Q28743161-83649C03-1339-42B5-8889-F00F45E7BF28Q30468926-8A958D37-1FB9-4D48-964B-77465E5BB751Q34554118-789AC589-A5AB-480E-8CB8-95E0B657F8D9Q37592716-B774795C-613A-4C54-8ABC-4A98930CC0A9Q37898391-DBE1DC32-DBF6-4487-80F1-449FB10458A2Q37985180-03E7A278-4EE5-4802-A158-BF0046AF4B2BQ38154384-A61CD312-75D3-4589-A5A7-B3F15574EC51Q38889407-D6C74353-7948-4A1A-BB11-C2E4437D576DQ39703504-5E50BA81-C17B-4F29-B556-DDA5CAAB9222Q40723712-05923665-DA8C-421E-8717-5493AB0E52EAQ41632530-FE6091BF-D406-4A86-99C6-133222BA1F17Q41632545-AA0334DC-DEFE-4389-80B3-0594FB59816EQ42669055-4981AE38-22F1-4BA1-A9D5-BE24978D2560Q45806876-57FD256C-7333-44D6-B88F-89E7A594E4DEQ45837762-6F4EA3A8-F94B-4507-BF5B-B66855179B2CQ45916858-F772B34E-3CA8-4737-BBFF-013FC309CF4FQ45934263-1B23F503-94EC-4105-AB25-65D500FC6F0FQ46079869-CECD0439-2CF3-4E58-B25A-FC29C69A09A8Q46846254-A09AFAD7-3E70-4E66-8BB2-AAFD9E6B5E48Q46897797-AF5BC007-B9AD-486D-9F6A-7F988F2097D0Q47105750-8E6E9B11-B692-40E2-9B6E-EDE64E65E35FQ47178270-DC757AE4-7B9D-4C54-84BA-6EEA92B7616BQ47420218-7D679E7E-6D8E-4AA9-AB92-EB36F3F61E2CQ47827229-805D9238-7131-431A-B6DB-EBBEB86F9719Q47946248-EBF25F6F-A7F8-41DE-AAAD-C0A05A0D5573Q48160717-96018E85-38E7-4275-A215-AA32098CF114Q48337593-49882700-98A2-485D-AADF-CCF792EDFFF5Q51725678-A954B713-7736-4635-B116-89DD689FB818Q83453001-02DD8F09-3172-4E81-9A32-5DBE53A0DAB6Q89144522-644860F4-DCD3-4F28-9279-B7CDF83C26D1Q94520043-56AD4AE1-6E44-4FD3-BA5D-D72A5394DE3CQ95610568-D2B21540-C5C0-4ED3-81DC-6B3CA05BCB44Q95627728-F3EE5C3F-950D-455F-9554-811A5163E6B3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcela Vizcaychipi
@ast
Marcela Vizcaychipi
@en
Marcela Vizcaychipi
@es
Marcela Vizcaychipi
@nl
Marcela Vizcaychipi
@sl
type
label
Marcela Vizcaychipi
@ast
Marcela Vizcaychipi
@en
Marcela Vizcaychipi
@es
Marcela Vizcaychipi
@nl
Marcela Vizcaychipi
@sl
altLabel
Dr MPV
@en
prefLabel
Marcela Vizcaychipi
@ast
Marcela Vizcaychipi
@en
Marcela Vizcaychipi
@es
Marcela Vizcaychipi
@nl
Marcela Vizcaychipi
@sl
P1053
H-5487-2011
P106
P1153
15842738400
P21
P31
P3829
P496
0000-0001-7894-873X